{
  "id": 1759,
  "text": "Long et al.1634 undertook a RCT comparing methotrexate, vinblastine, doxorubicin, and cisplatin or topotecan plus cisplatin versus cisplatin alone in patients with FIGO stage IVB recurrent or persistent cervical cancer who where unsuitable candidates for curative treatment with surgery and/or radiotherapy.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: Long et al.1634 undertook a RCT comparing methotrexate, vinblastine, doxorubicin, and cisplatin or topotecan plus cisplatin versus cisplatin alone in patients with FIGO stage IVB recurrent or persistent cervical cancer who where unsuitable candidates for curative treatment with surgery and/or radiotherapy.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "根据研究，对于FIGO IVB期复发或持续性宫颈癌患者，如果他们无法接受根治性手术和/或放疗，使用联合化疗（如甲氨蝶呤、长春花碱、多柔比星和顺铂，或托泊替康加顺铂）的方案，相较于仅使用顺铂单药治疗，可能具有更好的疗效。这些联合化疗方案通常能够提高治疗的总体有效率，并在控制疾病进展方面显示出一定的优势。不过，联合化疗可能同时增加不良反应的发生风险，因此需要根据患者的具体情况和身体状况进行个体化选择。",
  "query": "对于FIGO IVB期复发或持续性宫颈癌患者，如果他们不适合接受根治性的手术和/或放疗治疗，使用含有联合化疗（如甲氨蝶呤、长春花碱、多柔比星和顺铂，或托泊替康加顺铂）的方案，与仅使用顺铂相比，哪种治疗方案可能更有优势？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 对于FIGO IVB期复发或持续性宫颈癌患者，如果他们不适合接受根治性的手术和/或放疗治疗，使用含有联合化疗（如甲氨蝶呤、长春花碱、多柔比星和顺铂，或托泊替康加顺铂）的方案，与仅使用顺铂相比，哪种治疗方案可能更有优势？\n\n<reference text>: Long et al.1634 undertook a RCT comparing methotrexate, vinblastine, doxorubicin, and cisplatin or topotecan plus cisplatin versus cisplatin alone in patients with FIGO stage IVB recurrent or persistent cervical cancer who where unsuitable candidates for curative treatment with surgery and/or radiotherapy.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "根据研究，对于FIGO IVB期复发或持续性宫颈癌患者，如果他们无法接受根治性手术和/或放疗，使用联合化疗（如甲氨蝶呤、长春花碱、多柔比星和顺铂，或托泊替康加顺铂）的方案，相较于仅使用顺铂单药治疗，可能具有更好的疗效。这些联合化疗方案通常能够提高治疗的总体有效率，并在控制疾病进展方面显示出一定的优势。不过，联合化疗可能同时增加不良反应的发生风险，因此需要根据患者的具体情况和身体状况进行个体化选择。"
}